1
|
Ye Q, Zhou Y, Xu K, Jiang Z. Causality of blood metabolites and metabolic pathways on peripheral arteriosclerosis: a Mendelian randomization study. Front Nutr 2024; 11:1421531. [PMID: 39296501 PMCID: PMC11409423 DOI: 10.3389/fnut.2024.1421531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Accepted: 08/20/2024] [Indexed: 09/21/2024] Open
Abstract
Background Peripheral arteriosclerosis is caused by any atherosclerosis outside the heart and brain. However, the underlying biological mechanisms are not fully understood. This study aims to explore the causal relationship between blood metabolites and peripheral arteriosclerosis. Methods A Mendelian randomization (MR) analysis was implemented to estimate the causality of blood metabolites on peripheral arteriosclerosis. A genome-wide association study (GWAS) of 1,400 metabolites was used as the exposure, whereas two different GWAS datasets of peripheral arteriosclerosis were the outcomes. Inverse-variance weighted (IVW) was the main analysis of causal analysis. MR-Egger, the simple mode, weighted median and weighted mode were used to increase the stability and robustness of the results. Cochran Q test, MR-Egger intercept test, the funnel plot, and MR-Pleiotropy RESidual Sum and Outlier were used for sensitivity analyses. Furthermore, metabolic pathway enrichment analysis was performed using MetaboAnalyst5.0. Results In this MR study, eight blood metabolites have a strong causal relationship with peripheral arteriosclerosis, including 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4), 1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6), 1-(1-enyl-stearoyl)-2-arachidonoyl-GPE, 1-palmitoyl-2-dihomo-linolenoyl-GPC, Gamma-glutamylleucine, Deoxycholic acid glucuronide and two named X- (X-24546, X-26111). In addition, five important metabolic pathways in peripheral arteriosclerosis were identified through metabolic pathway analysis. Conclusion This study provides evidence for the causal relationship between blood metabolites and peripheral arteriosclerosis, and these eight blood metabolites provide new perspectives for screening and prevention of peripheral arteriosclerosis in the future.
Collapse
Affiliation(s)
- Qian Ye
- Department of Clinical Laboratory, Wenzhou People's Hospital, The Third Affiliated Hospital of Shanghai University, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Yilin Zhou
- College of Engineering, Boston University, Boston, MA, United States
| | - Kai Xu
- Department of Clinical Laboratory, Wenzhou People's Hospital, The Third Affiliated Hospital of Shanghai University, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Zhili Jiang
- Cardiac Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| |
Collapse
|
2
|
Ismaeel A, Lavado R, Koutakis P. Metabolomics of peripheral artery disease. Adv Clin Chem 2022; 106:67-89. [PMID: 35152975 DOI: 10.1016/bs.acc.2021.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The science of metabolomics has emerged as a novel tool for studying changes in metabolism that accompany different disease states. Several studies have applied this evolving field to the study of various cardiovascular disease states, which has led to improved understanding of metabolic changes that underlie heart failure and ischemic heart disease. A significant amount of progress has also been made in the identification of novel biomarkers of cardiovascular disease. Another common atherosclerotic disease, peripheral artery disease (PAD) affects arteries of the lower extremities. Although certain aspects of the disease pathophysiology overlap with other cardiovascular diseases in general, PAD patients suffer unique manifestations that lead to significant morbidity and mortality as well as severe functional limitations. Furthermore, because over half of PAD patients are asymptomatic, there is a need for improved diagnostic and screening methods. Identification of metabolites associated with the disease may thus be a promising approach for PAD. However, PAD remains highly understudied. In this chapter, we discuss the application of metabolomics to the study of PAD.
Collapse
Affiliation(s)
- Ahmed Ismaeel
- Department of Biology, Baylor University, Waco, TX, United States
| | - Ramon Lavado
- Department of Environmental Science, Baylor University, Waco, TX, United States
| | | |
Collapse
|
3
|
Old and New Biomarkers Associated with Endothelial Dysfunction in Chronic Hyperglycemia. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2022; 2021:7887426. [PMID: 34987703 PMCID: PMC8723873 DOI: 10.1155/2021/7887426] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 11/18/2021] [Accepted: 11/20/2021] [Indexed: 11/18/2022]
Abstract
Chronic hyperglycemia and vascular damage are strictly related. Biomarkers of vascular damage have been intensively studied in the recent years in the quest of reliable cardiovascular risk assessment tools able to facilitate risk stratification and early detection of vascular impairment. The present study is a narrative review with the aim of revising the available evidence on current and novel markers of hyperglycemia-induced vascular damage. After a discussion of classic tools used to investigate endothelial dysfunction, we provide an in-depth description of novel circulating biomarkers (chemokines, extracellular vesicles, and epigenetic and metabolomic biomarkers). Appropriate use of a single as well as a cluster of the discussed biomarkers might enable in a near future (a) the prompt identification of targeted and customized treatment strategies and (b) the follow-up of cardiovascular treatment efficacy over time in clinical research and/or in clinical practice.
Collapse
|
4
|
On the Role of Paraoxonase-1 and Chemokine Ligand 2 (C-C motif) in Metabolic Alterations Linked to Inflammation and Disease. A 2021 Update. Biomolecules 2021; 11:biom11070971. [PMID: 34356595 PMCID: PMC8301931 DOI: 10.3390/biom11070971] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 06/23/2021] [Accepted: 06/29/2021] [Indexed: 02/08/2023] Open
Abstract
Infectious and many non-infectious diseases share common molecular mechanisms. Among them, oxidative stress and the subsequent inflammatory reaction are of particular note. Metabolic disorders induced by external agents, be they bacterial or viral pathogens, excessive calorie intake, poor-quality nutrients, or environmental factors produce an imbalance between the production of free radicals and endogenous antioxidant systems; the consequence being the oxidation of lipids, proteins, and nucleic acids. Oxidation and inflammation are closely related, and whether oxidative stress and inflammation represent the causes or consequences of cellular pathology, both produce metabolic alterations that influence the pathogenesis of the disease. In this review, we highlight two key molecules in the regulation of these processes: Paraoxonase-1 (PON1) and chemokine (C-C motif) ligand 2 (CCL2). PON1 is an enzyme bound to high-density lipoproteins. It breaks down lipid peroxides in lipoproteins and cells, participates in the protection conferred by HDL against different infectious agents, and is considered part of the innate immune system. With PON1 deficiency, CCL2 production increases, inducing migration and infiltration of immune cells in target tissues and disturbing normal metabolic function. This disruption involves pathways controlling cellular homeostasis as well as metabolically-driven chronic inflammatory states. Hence, an understanding of these relationships would help improve treatments and, as well, identify new therapeutic targets.
Collapse
|
5
|
Rodríguez-Tomàs E, Arenas M, Gómez J, Acosta J, Trilla J, López Y, Árquez M, Torres L, Araguas P, Hernández-Aguilera A, Baiges-Gaya G, Castañé H, Camps J, Joven J. Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy. PLoS One 2021; 16:e0250453. [PMID: 33886674 PMCID: PMC8062076 DOI: 10.1371/journal.pone.0250453] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 04/07/2021] [Indexed: 12/16/2022] Open
Abstract
We report a pilot study on the feasibility of determinations of circulating levels of paraoxonase-1 (PON1) and compounds related to energy metabolism as biomarkers for the evaluation of patients with rectal cancer (RC), and the effects produced by neoadjuvant radiochemotherapy (NRCT). We studied 32 patients treated with radiotherapy plus capecitabine concomitant chemotherapy and 48 control subjects. We identified pre-NRCT PON1 and α-ketoglutarate as the parameters that best discriminated between RC patients and the control group. Receiver operating characteristics analysis of the combination of the two parameters showed an area under the curve (AUC) of 0.918. Moreover, patients who presented a pathological complete response (pCR) to treatment had lower plasma pre-NRCT valine concentrations (AUC of 0.826). Patients who had a relapse had lower concentrations of succinate (AUC of 0.833). The results of the present study illustrate the usefulness of investigating alterations in oxidative stress and metabolism in RC. Due to the small number of patients studied, our results must be considered preliminary, but they suggest that the determination of circulating levels of PON1 and α-ketoglutarate might be a valuable tool for the early diagnosis of RC, while the determination of valine and succinate might effectively predict pCR and the appearance of relapse.
Collapse
Affiliation(s)
- Elisabet Rodríguez-Tomàs
- Unitat de Recerca Biomèdica, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Meritxell Arenas
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
- * E-mail: (MA); (JC)
| | - Junior Gómez
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Johana Acosta
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Jordi Trilla
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Yolanda López
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Miguel Árquez
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Laura Torres
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Pablo Araguas
- Department of Radiation Oncology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Anna Hernández-Aguilera
- Unitat de Recerca Biomèdica, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
- Department of Pathology, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Gerard Baiges-Gaya
- Unitat de Recerca Biomèdica, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Helena Castañé
- Unitat de Recerca Biomèdica, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| | - Jordi Camps
- Unitat de Recerca Biomèdica, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
- * E-mail: (MA); (JC)
| | - Jorge Joven
- Unitat de Recerca Biomèdica, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain
| |
Collapse
|
6
|
Khan T, Loftus TJ, Filiberto AC, Ozrazgat-Baslanti T, Ruppert MM, Bandhyopadyay S, Laiakis EC, Arnaoutakis DJ, Bihorac A. Metabolomic Profiling for Diagnosis and Prognostication in Surgery: A Scoping Review. Ann Surg 2021; 273:258-268. [PMID: 32482979 PMCID: PMC7704904 DOI: 10.1097/sla.0000000000003935] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE This review assimilates and critically evaluates available literature regarding the use of metabolomic profiling in surgical decision-making. BACKGROUND Metabolomic profiling is performed by nuclear magnetic resonance spectroscopy or mass spectrometry of biofluids and tissues to quantify biomarkers (ie, sugars, amino acids, and lipids), producing diagnostic and prognostic information that has been applied among patients with cardiovascular disease, inflammatory bowel disease, cancer, and solid organ transplants. METHODS PubMed was searched from 1995 to 2019 to identify studies investigating metabolomic profiling of surgical patients. Articles were included and assimilated into relevant categories per PRISMA-ScR guidelines. Results were summarized with descriptive analytical methods. RESULTS Forty-seven studies were included, most of which were retrospective studies with small sample sizes using various combinations of analytic techniques and types of biofluids and tissues. Results suggest that metabolomic profiling has the potential to effectively screen for surgical diseases, suggest diagnoses, and predict outcomes such as postoperative complications and disease recurrence. Major barriers to clinical adoption include a lack of high-level evidence from prospective studies, heterogeneity in study design regarding tissue and biofluid procurement and analytical methods, and the absence of large, multicenter metabolome databases to facilitate systematic investigation of the efficacy, reproducibility, and generalizability of metabolomic profiling diagnoses and prognoses. CONCLUSIONS Metabolomic profiling research would benefit from standardization of study design and analytic approaches. As technologies improve and knowledge garnered from research accumulates, metabolomic profiling has the potential to provide personalized diagnostic and prognostic information to support surgical decision-making from preoperative to postdischarge phases of care.
Collapse
Affiliation(s)
- Tabassum Khan
- Department of Surgery, University of Florida, Gainesville,
FL, USA
| | - Tyler J. Loftus
- Department of Surgery, University of Florida, Gainesville,
FL, USA
| | | | - Tezcan Ozrazgat-Baslanti
- Department of Medicine, University of Florida, Gainesville,
FL, USA
- Precision and Intelligent Systems in Medicine (PrismaP),
University of Florida, Gainesville, FL
| | | | - Sabyasachi Bandhyopadyay
- Department of Medicine, University of Florida, Gainesville,
FL, USA
- Precision and Intelligent Systems in Medicine (PrismaP),
University of Florida, Gainesville, FL
| | - Evagelia C. Laiakis
- Department of Oncology, Georgetown University, Washington
DC, USA
- Department of Biochemistry and Molecular & Cellular
Biology, Georgetown University, Washington DC, USA
| | | | - Azra Bihorac
- Department of Medicine, University of Florida, Gainesville,
FL, USA
- Precision and Intelligent Systems in Medicine (PrismaP),
University of Florida, Gainesville, FL
| |
Collapse
|
7
|
Serum Metabolic Signatures of Chronic Limb-Threatening Ischemia in Patients with Peripheral Artery Disease. J Clin Med 2020; 9:jcm9061877. [PMID: 32560175 PMCID: PMC7355749 DOI: 10.3390/jcm9061877] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 05/30/2020] [Accepted: 06/10/2020] [Indexed: 12/11/2022] Open
Abstract
Peripheral artery disease (PAD) is characterized by the atherosclerotic narrowing of lower limb vessels, leading to ischemic muscle pain in older persons. Some patients experience progression to advanced chronic limb-threatening ischemia (CLTI) with poor long-term survivorship. Herein, we performed serum metabolomics to reveal the mechanisms of PAD pathophysiology that may improve its diagnosis and prognosis to CLTI complementary to the ankle-brachial index (ABI) and clinical presentations. Non-targeted metabolite profiling of serum was performed by multisegment injection-capillary electrophoresis-mass spectrometry (MSI-CE-MS) from age and sex-matched, non-diabetic, PAD participants who were recruited and clinically stratified based on the Rutherford classification into CLTI (n = 18) and intermittent claudication (IC, n = 20). Compared to the non-PAD controls (n = 20), PAD patients had lower serum concentrations of creatine, histidine, lysine, oxoproline, monomethylarginine, as well as higher circulating phenylacetylglutamine (p < 0.05). Importantly, CLTI cases exhibited higher serum concentrations of carnitine, creatinine, cystine and trimethylamine-N-oxide along with lower circulating fatty acids relative to well matched IC patients. Most serum metabolites associated with PAD progression were also correlated with ABI (r = ±0.24-0.59, p < 0.05), whereas the ratio of stearic acid to carnitine, and arginine to propionylcarnitine differentiated CLTI from IC with good accuracy (AUC = 0.87, p = 4.0 × 10-5). This work provides new biochemical insights into PAD progression for the early detection and surveillance of high-risk patients who may require peripheral vascular intervention to prevent amputation and premature death.
Collapse
|
8
|
Chen L, Wei J, Zhu H, Pan H, Fang D. Energy supplementation rescues growth restriction and female infertility of mice with hepatic HRD1 ablation. Am J Transl Res 2020; 12:2018-2027. [PMID: 32509196 PMCID: PMC7270037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 03/10/2020] [Indexed: 06/11/2023]
Abstract
Severe dietary restriction, catabolic states and even short-term caloric deprivation impair fertility in mammals including human, which is often reversible by restoration of the energy supplementation. The dysregulated crosstalk among multiple organs is possibly involved in this process. However, ideal experimental animal models are needed to illuminate functional crosstalk among distal organs during the starvation pathogenesis. We have recently discovered that conditional hepatic HRD1 gene deletion results in elevated energy expenditure and consequently leads to growth retardation and female fertility. Herein, we discovered that both growth retardation and female infertility of liver-specific HRD1 knockout mice could be fully rescued by additional energy supplementation upon HFD feeding. Hepatic HRD1 deletion appears to impair by the pituitary gland functions in secreting critical hormones in growth and female fertility including growth hormone (GH), follicle-stimulating hormone (FSH) and luteinizinghormone (LH) because a dramatic reduction in the sera levels of all three hormones were detected in liver HRD1 KO mice, which consequently shortened their tibia lengths and impaired the ovary functions in females. HFD feeding for six weeks largely restored all three hormones in liver HRD1 KO mice back to levels comparable with those in WT mice. In addition, the growth hormone induced activation of JAK-STAT5 pathway was inhibited by HRD1 deletion, and additional energy supplementation upon HFD feeding restored STAT5 transcriptional activation. Our studies establish a unique mouse model to study liver crosstalk with distal organs in regulating energy balance in growth and female fertility.
Collapse
Affiliation(s)
- Lu Chen
- Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical ScienceBeijing 100730, China
| | - Juncheng Wei
- Department of Pathology, Northwestern University Feinberg School of MedicineChicago, IL 60611, USA
| | - Huijuan Zhu
- Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical ScienceBeijing 100730, China
| | - Hui Pan
- Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical ScienceBeijing 100730, China
| | - Deyu Fang
- Department of Pathology, Northwestern University Feinberg School of MedicineChicago, IL 60611, USA
| |
Collapse
|
9
|
Goïta Y, Chao de la Barca JM, Keïta A, Diarra MB, Dembélé KC, Chabrun F, Dramé BSI, Kassogué Y, Diakité M, Mirebeau-Prunier D, Cissé BM, Simard G, Reynier P. Sexual Dimorphism of Metabolomic Profile in Arterial Hypertension. Sci Rep 2020; 10:7517. [PMID: 32371946 PMCID: PMC7200712 DOI: 10.1038/s41598-020-64329-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Accepted: 04/07/2020] [Indexed: 12/18/2022] Open
Abstract
Metabolomic studies have demonstrated the existence of biological signatures in blood of patients with arterial hypertension, but no study has hitherto reported the sexual dimorphism of these signatures. We compared the plasma metabolomic profiles of 28 individuals (13 women and 15 men) with essential arterial hypertension with those of a healthy control group (18 women and 18 men), using targeted metabolomics. Among the 188 metabolites explored, 152 were accurately measured. Supervised OPLS-DA (orthogonal partial least squares-discriminant analysis) showed good predictive performance for hypertension in both sexes (Q2cum = 0.59 in women and 0.60 in men) with low risk of overfitting (p-value-CV ANOVA = 0.004 in women and men). Seventy-five and 65 discriminant metabolites with a VIP (variable importance for the projection) greater than 1 were evidenced in women and men, respectively. Both sexes showed a considerable increase in phosphatidylcholines, a decrease in C16:0 with an increase in C28:1 lysophosphatidylcholines, an increase in sphingomyelins, as well as an increase of symmetric dimethylarginine (SDMA), acetyl-ornithine and hydroxyproline. Twenty-nine metabolites, involved in phospholipidic and cardiac remodeling, arginine/nitric oxide pathway and antihypertensive and insulin resistance mechanisms, discriminated the metabolic sexual dimorphism of hypertension. Our results highlight the importance of sexual dimorphism in arterial hypertension.
Collapse
Affiliation(s)
- Yaya Goïta
- Faculté de Pharmacie, Université des Sciences, des Techniques et des Technologies, de Bamako, Mali
- Service de Cardiologie, Centre Hospitalier Universitaire Mère-Enfant (CHUME) et Laboratoire d'analyses de Biologie médicale et Anatomo-Pathologique, Centre Hospitalier Universitaire Hôpital du Mali, Bamako, Mali
- Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France
- Unité Mixte de Recherche Mitovasc, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, Centre National de la Recherche Scientifique (CNRS) 6015, Université d'Angers, Angers, France
| | - Juan Manuel Chao de la Barca
- Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France
- Unité Mixte de Recherche Mitovasc, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, Centre National de la Recherche Scientifique (CNRS) 6015, Université d'Angers, Angers, France
| | - Asmaou Keïta
- Service de Cardiologie, Centre Hospitalier Universitaire Mère-Enfant (CHUME) et Laboratoire d'analyses de Biologie médicale et Anatomo-Pathologique, Centre Hospitalier Universitaire Hôpital du Mali, Bamako, Mali
| | - Mamadou Bocary Diarra
- Service de Cardiologie, Centre Hospitalier Universitaire Mère-Enfant (CHUME) et Laboratoire d'analyses de Biologie médicale et Anatomo-Pathologique, Centre Hospitalier Universitaire Hôpital du Mali, Bamako, Mali
| | - Klétigui Casimir Dembélé
- Faculté de Pharmacie, Université des Sciences, des Techniques et des Technologies, de Bamako, Mali
- Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France
- Unité Mixte de Recherche Mitovasc, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, Centre National de la Recherche Scientifique (CNRS) 6015, Université d'Angers, Angers, France
| | - Floris Chabrun
- Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France
- Unité Mixte de Recherche Mitovasc, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, Centre National de la Recherche Scientifique (CNRS) 6015, Université d'Angers, Angers, France
| | - Boubacar Sidiki Ibrahim Dramé
- Faculté de Pharmacie, Université des Sciences, des Techniques et des Technologies, de Bamako, Mali
- Laboratoire d'analyses de Biologie médicale et Anatomo-Pathologique, Centre Hospitalier Universitaire Hôpital du Mali, Bamako, Mali
| | - Yaya Kassogué
- Faculté de Pharmacie, Université des Sciences, des Techniques et des Technologies, de Bamako, Mali
| | - Mahamadou Diakité
- Faculté de Pharmacie, Université des Sciences, des Techniques et des Technologies, de Bamako, Mali
| | - Delphine Mirebeau-Prunier
- Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France
- Unité Mixte de Recherche Mitovasc, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, Centre National de la Recherche Scientifique (CNRS) 6015, Université d'Angers, Angers, France
| | - Bakary Mamadou Cissé
- Faculté de Pharmacie, Université des Sciences, des Techniques et des Technologies, de Bamako, Mali
| | - Gilles Simard
- Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France
| | - Pascal Reynier
- Departement de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France.
- Unité Mixte de Recherche Mitovasc, Institut National de la Santé et de la Recherche Médicale (INSERM) U1083, Centre National de la Recherche Scientifique (CNRS) 6015, Université d'Angers, Angers, France.
| |
Collapse
|